NEW YORK, Aug. 20, 2024 (GLOBE NEWSWIRE) -- __________________ WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Moderna, Inc. (NASDAQ: MRNA) between January 18, 2023 and June 25, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 8, 2024. SO WHAT: If you purchased Moderna securities du ...

SAN DIEGO, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Moderna, Inc. (NASDAQ: MRNA) securities between January 18, 2023 and June 25, 2024. Moderna is a biotechnology company that discovers, develops, and commercializes messenger RNA ("mRNA") therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular dise ...

NEW YORK, Aug. 20, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Moderna, Inc. ("Moderna" or the "Company") (NASDAQ: MRNA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Moderna investors who were adversely affected by alleged securities fraud between January 18, 2023 and June 25, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/moderna-lawsuit-submission-form?pri ...

NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Moderna, Inc. ("Moderna" or the "Company") (NASDAQ: MRNA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Moderna investors who were adversely affected by alleged securities fraud between January 18, 2023 and June 25, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/moderna-lawsuit-submission-form ...

NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired the securities of Moderna, Inc. ("Moderna") (NASDAQ: MRNA) between January 18, 2023 and June 25, 2024, inclusive (the "Class Period"). For more information, submit a form at Moderna, Inc. Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pallocco@bernlieb.com, or call us at ...

Moderna Today MRNA Moderna $90.28 +3.44 (+3.96%) 52-Week Range $62.55 ▼ $170.47 Price Target $124.07 Add to Watchlist Biotechnology company Moderna Inc. NASDAQ: MRNA stock rocked investors with a 30% drop following its second-quarter 2024 earnings release. The company disappointed investors when it revised its respiratory franchise revenue forecast lower by half a billion dollars. However, shares were able to bounce off their low of $78.07 and start to climb back. While COVID is no longer a pandemic, it is ...

NEW YORK, Aug. 19, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Moderna, Inc. (NASDAQ: MRNA). Shareholders who purchased shares of MRNA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/moderna-loss-submission-form/?id=96012&from=4 CLASS PERIOD: January 18, 2023 to June 25, ...

文章核心观点 - 文章报道了Bragar Eagel & Squire, P.C.律师事务所代表股东对Moderna, Inc.和Sprinklr, Inc.提起的集体诉讼，涉及公司财务和业务前景的虚假陈述[1][3] Moderna, Inc.相关信息 - **集体诉讼期间**：2023年1月18日至2024年6月25日[2] - **主要原告截止日期**：2024年10月8日[2] - **指控内容**：公司在其业务、运营和前景方面做出了实质性的虚假和误导性陈述，具体包括mRNA-1345的有效性被夸大，其临床和商业前景被高估，导致公司公开声明在相关时间内具有实质性的虚假性[3] Sprinklr, Inc.相关信息 - **集体诉讼期间**：2023年3月29日至2024年6月5日[3] - **主要原告截止日期**：2024年10月14日[3] - **事件描述**：2023年12月6日，Sprinklr宣布了强劲的2024年第三季度业绩，但随后下调了2025年第四季度和全年的增长预期，归因于宏观经济逆风和销售策略的过度转向CCaaS市场。2024年6月5日，公司再次宣布大幅降低2025财年的增长预期，降至仅7%的年增长率，原因是核心业务客户保留率下降和宏观经济逆风[4][5] - **股价影响**：Sprinklr的股价在宣布下调预期后，从2023年9月的每股$16.70下跌至$11.11，跌幅约34%。2024年6月5日至6日，股价从$10.84跌至$9.20，单日跌幅超过15%[4][5]

NEW YORK, Aug. 17, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Moderna, Inc. ("Moderna" or the "Company") (NASDAQ: MRNA) and certain officers. The class action, filed in the United States District Court for the District of Massachusetts, and docketed under 24- cv- 12058, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Moderna securities between January 18, 2023 and June 25, 2024, bot ...

NEW YORK, Aug. 16, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Moderna, Inc. (NASDAQ: MRNA) between January 18, 2023 and June 25, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 8, 2024. SO WHAT: If you purchased Moderna securities during the Class Peri ...